Significant fluid and electrolyte disturbances occur in extremely low birth weight (ELBW) infants in the first few days of life. We investigated the effect of semipermeable polyurethane membrane (Tegaderm s ) applied to the skin shortly after birth on fluid and electrolyte status and the clinical outcome in these infants.
INTRODUCTION
The skin of extremely low birth weight (ELBW) infants lacks keratin and has a very immature stratum corneum. [1] [2] [3] [4] Thus, large transepidermal water losses (TEWL) occur early in life. 5, 6 This large evaporative loss of free water leads to marked fluid losses 3 and results in significant morbidity secondary to clinical dehydration. 7 Electrolyte disturbances that include severe hypernatremia and hyperosmolar dehydration are seen more often in the most immature preterms. [8] [9] [10] Treatment includes high-volume fluid replacement which carries its own risks and complications. 7, 11 Tegaderm s (3M, St. Paul, MN, USA) is a thin, semipermeable, polyurethane membrane with a self-adhesive surface on one side. When applied to ELBW infants as an artificial skin, it has been shown to significantly reduce TEWL without interfering with the skin integrity and development. 12, 13 Knauth et al. 12 and Vernon et al. 13 applied adherent patches to the chest and abdomen or the thigh for 4 to 14 days. They demonstrated significantly decreased TEWL over those areas compared to the adjacent noncovered skin. Once the membrane patches were removed, TEWL increased and were similar to the adjacent skin.
In the past few years, we have routinely applied Tegaderm to large skin areas of ELBW infants in our neonatal intensive care unit (NICU). We have observed a reduction in the early fluid and electrolyte disturbances, in the need for frequent laboratory tests, as well as in the total daily fluid requirement during the first few days of life. Our objectives for this study were: (1) to evaluate the effect of Tegaderm s application to the skin on fluid and electrolyte status during the first week of life and (2) to assess whether the effect of Tegaderm s , if any, affected the outcome of ELBW infants.
METHODS
In our NICU, Tegaderm s is applied generously to large areas of the body including the chest, abdomen, and all extremities shortly after birth. It remains attached to the skin for 2 to 3 weeks. Occasionally, partial removal from an extremity is needed for placement of an intravenous (IV) line. Infants are cared for under radiant warmers initially and then placed in incubators when clinically stable, as per standard nursery protocol.
To evaluate the effect of Tegaderm s application (initiated at the Albert Einstein Medical Center NICU in 1992), we reviewed the charts of ELBW (BW<1.0 kg) infants born during 24 consecutive months prior to starting Tegaderm s application (NOTEG) and 19 consecutive months after starting Tegaderm s (TEG). Prenatal maternal data were collected and compared. Neonatal data collected from the first week of life included daily weight, fluid intake and output, electrolytes and blood urea nitrogen (BUN) and serum creatinine. Respiratory outcome was assessed by the diagnosis of bronchopulmonary dysplasia (BPD), defined as the need for oxygen supplementation at 36 weeks corrected gestational age. The groups were compared for postnatal steroids use, length of ventilation and oxygen supplementation as well as requirement for oxygen at discharge to either their home or a transitional rehabilitation facility. Additional clinical morbidities compared included incidence of patent ductus arteriosus (PDA; confirmed by cardiac echocardiography), necrotizing enterocolitis (NEC; ZStage 2, modified Bell's criteria), intraventricular hemorrhage (IVH; by cranial ultrasonography by a pediatric radiologist), episodes of blood culture proven sepsis after 3 days of life, and incidence and severity of retinopathy of prematurity (ROP; assessed by a pediatric ophthalmologist).
The study was conducted as per the guidelines of the Albert Einstein Healthcare Network Institutional Review Board.
Statistical analysis included Student's t-test, w 2 -test, and repeated measures analysis of variance (ANOVA), as appropriate.
RESULTS

Patient Population
There were no differences in age at delivery, use of prenatal tocolytics, incidence of prolonged rupture of membranes, poor prenatal care, substance abuse, or sexually transmitted disease (as detected by Rapid Plasma Reagin test) among mothers of both groups (data not shown).
Infants in both NOTEG and TEG groups were similar for gestational age (26.1±1.9 vs 26.3±1.8 weeks) and weight (756±158 vs 802±160 g) at birth. There were no differences in the Apgar scores, mode of delivery, or the number of outborn infants (data not shown).
Fluid and Sodium Levels and BUN/Serum Creatinine during the First Week of Life Daily fluid intakes during the first week of life were significantly decreased in TEG infants when compared to the fluid requirements of NOTEG infants ( Figure 1 ) (P ¼ 0.003). In addition, the number of infants requiring daily fluid supplementation of Z170 ml/kg/ day was significantly decreased among those with Tegaderm s application, four TEG infants for a total of 10 days compared to 21 NOTEG infants, for a total of 84 days (P ¼ 0.0008) ( Table 1) .
Sodium levels were significantly lower in the TEG group when compared to NOTEG (P ¼ 0.03) (Figure 2 ). TEG infants also experienced significantly fewer occurrences of hypernatremia (sodium Z150 meq/L) throughout the first week of life, eight times in five TEG infants compared to 32 times in 20 NOTEG infants (P ¼ 0.0005) ( Table 1) .
Tegaderm s application was associated with significantly lower daily weight loss throughout the first week of life (P ¼ 0.04; data not shown). TEG infants also regained their birth weight faster, at a mean age of 16 days compared to a mean of 21 days for those with NOTEG (P ¼ 0.02) ( Table 1) .
There was no significant difference in the daily BUN and serum creatinine levels between the two groups of infants (data not shown) throughout the first week of life.
Survival and Clinical Outcome
The incidence of various clinical diagnoses is noted in Table 1 . Survival was significantly higher among TEG infants, 27 of 30 (90%) survived while in the NOTEG group only 25 of 39 (64%) infants survived (P ¼ 0.02). There were no significant differences in incidence of PDA, NEC, sepsis, and IVH of any grade between the two groups (Table 1) . Although the incidence of ROP was similar in both groups (54 vs 63%), in the NOTEG group, 48% of the disease was diagnosed at stage 3, and two patients, eventually required cryotherapy while in the TEG group only 16% reached severity of stage 3 and none reached threshold (P ¼ 0.046).
Respiratory Outcome of Survivors
The respiratory outcome of the infants who survived is detailed in Table 2 . Although not significantly different, the trend is toward a decreased time of ventilation and oxygen requirement among TEG infants. Infants in NOTEG group stayed an average of a week longer on ventilator and required oxygen for an average of 3 more weeks. However, BPD was significantly decreased in TEG infants (P ¼ 0.01). The use of antenatal (23 vs 13%) and postnatal (44 vs 47%) steroids as well as the proportion of infants receiving surfactant at birth (56 vs 63%) were similar in NOTEG and TEG groups.
Length of Hospitalization and Discharge
While the total days of hospitalization was similar in the two groups in the NICU, significantly more NOTEG infants required oxygen at discharge either to an interim rehabilitation facility or home (P ¼ 0.01) ( Table 2) .
DISCUSSION
Early application of Tegaderm s as an additional skin shield on ELBW infants was associated with significantly decreased sodium 
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Tegaderm s Use in ELBW Infants levels, daily fluid requirements and daily weight loss in the first few days of life. The incidence of hypernatremia was dramatically reduced as well as the need for daily fluid intake during the same time. As seen in Figure 2 , the variability of sodium levels was markedly decreased in the infants with Tegaderm s application to skin indicating better control with most sodium levels within the normal range. We feel that the decrease in sodium and fluid shifts during the critical early days of life may have contributed to the decreased morbidity and mortality.
The improvement in fluid and electrolyte management may be attributed to a decrease in TEWL in the areas covered with Tegaderm s . While we did not measure the rate of water loss in our patients, this has been reported by other investigators using different types of skin dressings.
12-15 Knauth et al. 12 applied two types of adhesive polyurethane patches (3 Â 3 cm) to the skin of the chest and abdomen for up to 4 days. They documented as much as a 50% decrease in TEWL over the covered skin areas when compared to the naked adjacent skin. Once the patches were removed, TEWL increased to a similar level as adjacent areas. They did not cover a large area of infant's skin and did not report on fluid and electrolyte status in their patients nor evaluated weight loss. Vernon et al. 13 applied a semipermeable polyurethane dressing to the right anterior chest or thigh for a 2-week period and found that in addition to lower TEWL over the treated areas, the number of bacteria did not increase beneath the semipermeable dressing nor was there any Malassezia furfur when compared to the nontreated side. A small study compared the safety and efficacy of a transparent adhesive dressing (n ¼ 6) to decrease TEWL in VLBW infants and found it significantly lower than in the control group (n ¼ 7).
14 Using a nonadhesive semipermeable dressing on the epidermal barrier of premature infants, investigators showed a consistently lower bacterial number and a significantly decreased TEWL. 15 TEWL is known to increase dramatically in the more extreme preterm infants. 16 TEWL is responsible for: (1) hypernatremic dehydration with marked weight loss during the first week of life, and (2) rapid increases in fluid maintenance requirements, often as high as 250 to 300 ml/kg/day. Once rehydrated, usually after the first 3 days of life, these infants can experience hyponatremia as well. 17 These rapid changes in sodium levels and fluid intake require frequent laboratory assessments and fluid adjustments, which contribute not only to significant morbidities but also to the hospitalization cost. High daily fluid maintenance can result in increased incidence and severity of BPD. 18 In our patients, incidence of BPD was significantly lower in the TEG group. They required a shorter period of mechanical ventilation and total days of oxygen supplementation, had fewer infants with tracheostomies and significantly fewer infants required supplemental oxygen at the time of discharge.
It is important to reiterate that an equal proportion (73%) of charts were reviewed in both epochs. Of the infants whose charts were reviewed, the survival rate was significantly higher among infants with early Tegaderm s application (90% compared to 64% of infants in the NOTEG group; Table 1 ). We realize that these survival rates occurred during consecutive periods. These rates, however, are similar to the overall survival rates of all the ELBW infants cared for in our NICU in the respective periods noted above (90 and 60% respectively). Importantly, besides the use of early Tegaderm s application, no additional changes in management of the extremely preterm infants occurred in our unit during these months. Maternal characteristics and management in both periods was similar as well. Prenatal steroids and postnatal surfactant administration are two therapeutic modalities that can influence survival and favor a better pulmonary outcome. In our study, however, prenatal steroids (used to enhance lung maturation which would result in a better respiratory outcome) were actually given to more mothers in the NOTEG group, yet TEG infants had the better pulmonary outcome. Furthermore, use of prenatal steroids have not been shown to impact on epidermal maturity. 19 In addition, postnatal surfactant use was also similar in both groups. Therefore, the improved survival rate in these consecutive periods may be attributed mostly to the initial stability in fluid and electrolyte status achieved with early Tegaderm s application to the immature fetal skin.
It is important to reiterate that we used Tegaderm s to cover a substantial portion of the exposed skin of the infant. We believe our results are reflective of this practice as TEWL may be variable from different parts of the immature skin 20 and hence, to have the optimum effect a large part of the immature skin needs to be covered.
By the time Tegaderm s is removed, the skin underneath has matured and has a normal appearance as has been confirmed by other investigators. 13, 15 We have not experienced any skin excoriation or depigmentation or any other adverse effects in ELBW babies managed with Tegaderm s . The dressing did not interfere with the monitoring of heart rate or breathing when carried out via electrodes attached to the covered areas as has been noted by others using a different synthetic dressing to cover and protect the skin. 21 Rutter 17 has suggested that the use of semipermeable polyurethane surgical dressing as an artificial skin may reduce skin damage in areas prone to consequent breakdown in sites where skin is in direct contact with skin, for example, in flexures such as axillae and groin. In another randomized study, premature infants with a semipermeable skin dressing (n ¼ 39; control group n ¼ 37) had skin which remained nonerythematous, intact, and undamaged under the dressing, whereas uncovered skin sustained significant breakdown in both groups. 22 Visscher et al. 23 have shown that semipermeable barriers applied to tape-stripped human adult skin lead to a more rapid restoration of the epidermal barrier than full occlusion or no occlusion at all. Early Tegaderm s application was also not associated with any skin infection or increased incidence of sepsis in our patients. In addition, we have not heard any negative remarks by any parents at our institution.
We feel that the clinical use of a semipermeable wound dressing such as Tegaderm s as an artificial skin is important, and highly relevant to neonatal intensive care, particularly as Aquaphor s , has been shown to be ineffective and possibly dangerous. [24] [25] [26] [27] [28] Although others have studied Tegaderm s applied temporarily to small areas of skin, this is the first study to report its use as a cover for large areas of the infant's skin for prolonged time periods. This is a retrospective study and unfortunately not all the charts were available for review. Since Tegaderm s has been in use at the AEMC NICU for the ELBW infants since 1992, we wanted to do a detailed analysis if what was being perceived as beneficial could be objectively verified. We selected the time frame that we felt would be most reliable to show a difference; about 2 years before and after the practice was initiated in our NICU. Furthermore, a similar proportion of charts were reviewed in both periods. While we agree that we have not proven a ''cause-and-effect'' relationship, our results are biologically plausible and extremely supportive of our claim that Tegaderm s appears to be beneficial in the care of the ELBW infant. We feel that our results are also ''timely'', in view of the disappointing results with Aquaphor s use, and the urgent need for skin protection in ELBW infants.
In summary, Tegaderm s application was associated with decreased fluctuation of serum sodium levels and daily fluid requirements during the first week of life in ELBW infants. Tegaderm s application is a safe and effective therapeutic modality to decrease the high TEWL of ELBW infants. Optimizing skin integrity in neonates, especially in the crucial first week of life, is an important step toward improving neonatal health. 29 The use of Tegaderm s in these infants may lead to improved pulmonary outcome and possibly better survival without risk to the infants. Furthermore, Tegaderm s may be more cost-effective and convenient for use in NICUs when compared to humidified isolettes, though topical oils have also shown promise. 30 A randomized controlled trial would be useful to definitively assess the benefits of using Tegaderm s , as suggested by our findings.
